New FDA Approval Expands Use of Cemiplimab in NSCLC : compar

The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.

Related Keywords

California , United States , Davidr Gandara , Jack West , University Of California , Twitter , Cancer Center , Drug Administration , Thoracic Oncology Program , City Of Hope Comprehensive Cancer Center , Comprehensive Cancer , Hope Comprehensive Cancer Center , Mirrors Everyday Practice , Lung Cancer , Ung Carcinoma , Ancer Lung , Skin Cancer , Alignant Skin Neoplasm , Chemotherapy , Combination Chemotherapy , Small Cell Lung Cancer , Cancer , Alignant Neoplasia , Arcinoma , Basal Cell Carcinoma , Asal Cell Carcinoma Of The Skin , Lung , Squamous Carcinoma , Biologic Therapy , Tumor , Platinum , Peripheral Neuropathy , Alopecia , Pain Management , Anaplastic Lymphoma Kinase Alk , Bulk ,